Drug news
Merck inc withdraws from oral vernakalant collaboration
Merck Inc., ceases development of the oral formulation of anti arrhythmic vernakalant which it has licensed from Cardiome Pharma of Canada.
The oral drug was being developed for long term prevention of atrial fibrillation recurrence. Merck Inc.,was influenced by its view of the regulatory environment and projected development timelines. Meck Inc., already markets the i.v. formulation as Brinavess in the EU and Latin America for rapid conversion of recurrent onset atrial fibrillation and plans further launches in 30 countries in 2012